Dialectical behavior therapy for borderline personality disorder
TR Lynch, WT Trost, N Salsman… - Annu. Rev. Clin …, 2007 - annualreviews.org
Since the introduction of Linehan's treatment manuals in 1993, dialectical behavior therapy
(DBT) has been widely disseminated throughout multiple therapeutic settings and applied to …
(DBT) has been widely disseminated throughout multiple therapeutic settings and applied to …
[HTML][HTML] The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects
T Lynch, AMY Price - American family physician, 2007 - aafp.org
Cytochrome P450 enzymes are essential for the metabolism of many medications. Although
this class has more than 50 enzymes, six of them metabolize 90 percent of drugs, with the …
this class has more than 50 enzymes, six of them metabolize 90 percent of drugs, with the …
Mechanisms of change in dialectical behavior therapy: Theoretical and empirical observations
Dialectical behavior therapy (DBT) can be considered a well‐established treatment for
borderline personality disorder (BPD) as evidenced by seven well‐controlled randomized …
borderline personality disorder (BPD) as evidenced by seven well‐controlled randomized …
[HTML][HTML] Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge… - … England Journal of …, 2010 - Mass Medical Soc
Background Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase
(ALK) are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of …
(ALK) are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of …
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Thirteen families have been described with an autosomal dominantly inherited dementia
named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP …
named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP …
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
LV Sequist, BA Waltman, D Dias-Santagata… - Science translational …, 2011 - science.org
Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …
[HTML][HTML] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib
TJ Lynch, DW Bell, R Sordella… - … England Journal of …, 2004 - Mass Medical Soc
Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …
[HTML][HTML] Early palliative care for patients with metastatic non–small-cell lung cancer
JS Temel, JA Greer, A Muzikansky… - … England Journal of …, 2010 - Mass Medical Soc
Background Patients with metastatic non–small-cell lung cancer have a substantial symptom
burden and may receive aggressive care at the end of life. We examined the effect of …
burden and may receive aggressive care at the end of life. We examined the effect of …
[HTML][HTML] Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose The EML4-ALK fusion oncogene represents a novel molecular target in a small
subset of non–small-cell lung cancers (NSCLC). To aid in identification and treatment of …
subset of non–small-cell lung cancers (NSCLC). To aid in identification and treatment of …
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial
MG Kris, RB Natale, RS Herbst, TJ Lynch Jr, D Prager… - Jama, 2003 - jamanetwork.com
ContextMore persons in the United States die from non–small cell lung cancer (NSCLC)
than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral …
than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral …